Product Hub: The growing potential of hiPS-derived beta cells
Christian Andersson, Product Development Manager at Takara Bio discusses hiPS-derived beta cells, which offer an unprecedented opportunity for diabetes research to model human physiology and ‘diseases in a dish’. Christian looks into the potential for new discoveries for diabetes and other metabolic diseases…
hiPS-derived beta cells offer an unprecedented opportunity for diabetes research to model human physiology and ‘diseases in a dish’. What are the major challenges for researchers that can be solved with the hiPS-derived beta cells you recently launched?
Many scientists rely on primary cells. Access to primary cells is limited; they are difficult to scale-up and the material suffers from high donor-to-donor variability. Primary islet cells for example are difficult to isolate, not easy to culture, and available in low numbers, which makes it hard to have enough material to run assays. The alternative of using immortalised cell lines from pancreatic islets is also not satisfying, as they behave like insulin secreting cancer cells with a non-relevant metabolism and strong resistance to apoptosis, limiting their interest for metabolic disease research. Our hiPS-derived beta cells provide a powerful solution to these problems.
The rest of this Product Hub is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!